Gain Therapeutics Inc (GANX)

Gianluca Fuggetta is the Senior Vice President Finance and Principal Financial Officer at GANX since January 6, 2025. " " He has progressed through various finance roles at GANX and previously built his career as an Assurance Manager at PwC. " "

Claude Nicaise, M.D. has over 35 years of experience in clinical and regulatory affairs and has been serving as an independent board member at GANX since January 2021. He has held leadership roles at major companies including Alexion Pharmaceuticals and Bristol-Myers Squibb. " " "

Dov Goldstein, M.D. serves as a Board Member and Audit Committee Chair at GANX since January 2021, leveraging his extensive background in science and financial management. " " He has over 20 years of experience and currently serves as the Chief Financial Officer of BioAge Labs, among other executive roles in the industry. "

Eric I. Richman has served as a Board Member at GANX since July 2020 after previously serving as CEO from June 2020 to September 2022, bringing over 30 years of experience in biotechnology and pharmaceuticals. " "

Gwen Melincoff has over 25 years of experience in business development and venture capital in the biotechnology and pharmaceutical industries, and she has served as a board member at GANX since January 2021. " " " She also contributes her expertise externally as Managing Director at Gemini Advisors LLC, Advisor at Verge Genomics, and as a board member at Protalix Biotherapeutics, Inc. and Collegium Pharmaceutical, Inc.. " " " "

Hans Peter Hasler has been serving as a member of the Board of Directors at GANX since January 2021. " " " He is an experienced leader in the biotechnology and pharmaceutical industries, having held positions such as Chairman of the Board at HBM Healthcare Investments AG and served as CEO at Vicarius Pharma AG until February 2020. " " " "

Jeffrey Riley has served as a Board Member at GANX since May 2019, also taking on key governance roles as Chair of the Compensation Committee and Audit Committee Member. " " " " " " " With over 25 years in the biotechnology and pharmaceutical industries, he strengthens strategic oversight at GANX while contributing to multiple organizations. "

Khalid Islam, Ph.D., is the co-founder and Chairman of the Board of Gain Therapeutics, Inc. since 2017. " " " He brings over 35 years of biotechnology experience and has held leadership roles in several pharmaceutical companies. " " "

Matthias Alder served as COO of GANX starting in October 2021 and was promoted to CEO and Board member on September 20, 2022, until his departure on June 25, 2024. " " " " He has over 25 years of experience in the pharmaceutical and biotechnology industries. " "